Novartis' Gilenya: Down But Not Out With NICE
Novartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.
Novartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.